Blocking VEGF function with Bevacizumab (Avastin®), a humanized monoclonal antibody directed against VEGF-A, is approved for use in several cancers, and has accelerated approval for relapsed/refractory GBM [16, 17]. This evidence concerns the gene VEGFA and cancer.